	PD09-07 Durvalumab in Combination with Bacillus Calmette-GuÃ©rin for Bacillus Calmette-GuÃ©rin-NaÃ¯ve, High-Risk Non-Muscle-Invasive Bladder Cancer: Primary Results from a US-Based, Phase IIIB, Open-Label, Single-Arm, Multicenter Study (PATAPSCO): Erratum. J Urol Jayram G, Shore ND, Tyson M, Pieczonka C, Treasure P, Gadzinski A, Mazzarella B, Hodari M, Glover K, Hardikar S, Hahn NM. PMID: 42713894 [PubMed - in process]
	Predicting postoperative acute kidney injury after colorectal cancer surgery: development and internal validation of a clinical prediction model using a nationwide cohort. BJS Open Skovsgaard M, Munch PV, Heide-Jørgensen U, Iversen LH, Christiansen CF. PMID: 42713840 [PubMed - indexed for MEDLINE]
	Comparison of Beiyi(Â®) and its reference product Enantone(Â®) as agonists of luteinizing hormone-releasing hormone against prostate cancer: a multicenter, randomized single-dose study. Front Pharmacol Yi Y, Shen P, Zheng T, Hou R, Fan L, Yu Y, Li J, Fang Y, Hao C, You P, Lu X, Lu X, Wei Q, Feng P. PMID: 42713047 [PubMed]
	Prognostic effect of the preoperative albumin-to-globulin ratio bladder cancer: a meta-analysis. Front Med (Lausanne) Huang F, Chen C, Mao Y, Lin T, Hu Q. PMID: 42712354 [PubMed]
	Metal artifact reduction for 3 T MRI-only prostate radiotherapy in patients with hip prostheses: impact on target definition, synthetic CT generation, dose calculation, and fiducial marker identification. Radiat Oncol Coskun M, Petersson JS, Wetterstedt SA, Brynolfsson P, Gustafsson CJ, Gunnlaugsson A, Olsson LE, Siversson C. PMID: 42711722 [PubMed - indexed for MEDLINE]
	Impact of Treatment Intensification with Abiraterone on Fracture-related Hospitalisation in Newly Diagnosed Prostate Cancer: A Secondary Analysis of Two Randomised Phase 3 Trials Within the STAMPEDE Trial Platform. Eur Urol Gray S, Dutey-Magni P, Jones C, Murphy LR, Murray ML, Brown JE, McCloskey E, Brown M, Amos CL, Gilbert DC, Jones RJ, Cross W, Matheson D, Millman R, STAMPEDE Collaborators, Parmar MKB, Sydes MR, Brown LC, Attard G, James ND, Clarke NW, Sachdeva A. PMID: 42711192 [PubMed - as supplied by publisher]
	Epidemiological trends in penile cancer and the evolving role of dynamic sentinel lymph node biopsy. Urol Oncol Hehir CM, Scanlon L, Calpin GG, Cullen IM. PMID: 42711149 [PubMed - as supplied by publisher]
	Detected Huge Urinoma With 99mTc-PSMA Activity on Initial Prostate Cancer Staging. Clin Nucl Med Ahmadi M, Samadi MH, Saber Tanha A, Askari E, Aslzare M, Dabbagh Kakhki VR. PMID: 42710082 [PubMed - indexed for MEDLINE]
	Graph neural network-based risk stratification of prostate cancer using gene expression and SHAP interpretability. PLoS One Pirmoradi S, Vaghefi Moghaddam S, Ardalan M, Sharifi Bonab MM, Teshnehlab M, Zununi Vahed S. PMID: 42709904 [PubMed - indexed for MEDLINE]
	Deep learning for automatic detection of prostatectomy in CT images of prostate cancer patients. Phys Eng Sci Med Rainio O, Li A, Vehmanen A, Jaakkola MK, Kemppainen J, Klén R. PMID: 42709364 [PubMed - as supplied by publisher]
	Refining risk stratification after indeterminate urinary cytology: Evidence from Bladder EpiCheck. Cancer Cytopathol Mercader C, Ingelmo-Torres M, Roldán FL, Figueras M, Villalba E, Galve P, Asiaín I, Costa M, Vilaseca A, Oriola J, Franco A, Alcaraz A, Mengual L. PMID: 42708821 [PubMed - indexed for MEDLINE]
	Research progress and clinical translation prospects of the urinary tract microbiome in prostate cancer. Front Immunol Li ZL, Qu RN, Liu SX, Wang W. PMID: 42707980 [PubMed - indexed for MEDLINE]
	Urinary Trace Element Concentrations in Congolese Patients With Prostate Cancer: A Case-Control Study. Prostate Cancer Mbey PM, Mukuku O, Saleh CU, Manika MM, Diangienda PDK, Moningo DM. PMID: 42707973 [PubMed]
	Frailty and [(177)Lu]Lu-PSMA-617 therapy: tools and strategies for older men with metastatic castration-resistant prostate cancer. Theranostics Bauckneht M, Borsellino N, Colloca GF, Fratino L, Santini D. PMID: 42707638 [PubMed - indexed for MEDLINE]
	Application of PathoChip to urine-derived nucleic acids for broad microbial profiling in men with suspected prostate cancer: setup of a methodological workflow and pilot feasibility study. J Liq Biopsy Mello-Grand M, Gregnanin I, Peraldo-Neia C, Ostano P, Guana F, Testino N, Malfitana V, Marchi G, Zaramella S, Robertson E, Chiorino G. PMID: 42707077 [PubMed]
	Lifestyle, anthropometric factors and clinically significant prostate cancer diagnosis in men with suspected prostate cancer. Scand J Urol Heiskanen E, Kalinen S, Chu RJ, Högerman M, Lamminen T, Taimen P, Jambor I, Aronen H, Merisaari H, Sainio T, Hakanen A, Ettala O, Laitinen K, Vasankari T, Kallonen T, Boström PJ, Promic study group. PMID: 42707024 [PubMed - indexed for MEDLINE]
	Artificial Intelligence in equivocal prostatic needle biopsies: benign mimics and cancer detection. Arch Ital Urol Androl Bawahab AA. PMID: 42707010 [PubMed - as supplied by publisher]
	MMP9 Knockout by CRISPR-Cas9 Reduces Bladder Cancer Malignancy But Does Not Synergize With BCG and Anti-PD-L1 in an Orthotopic Mouse Model. IUBMB Life Camargo JA, Lee MC, Souza MM, Silva LPD, Boas GCV, Silva KSD, Mioshi CM, Pimenta RCA, Candido P, Silva IAD, Trarbach EB, Leite KRM, Nahas WC, Reis STD. PMID: 42706676 [PubMed - indexed for MEDLINE]
	Multi-population GWAS meta-analysis identifies bladder cancer susceptibility loci and highlights genetic regulation of smoking-related risk. Nat Commun Prokunina-Olsson L, Florez-Vargas O, Levin MG, Dutta D, Breeze CE, Hurwitz LM, Yan W, Lamy P, Papenberg BW, Wang K, Lee CH, Milne RL, Gu J, Um CY, Joseph V, Furberg H, Le Calvez-Kelm F, Lori A, Choudhury PP, Afshar N, Kogevinas M, Offit K, Vermeulen SH, López de Maturana E, Albanes D, Purdue MP, Cortessis VK, Karagas MR, Kooperberg C, Bjurlin M, Tadesse DA, Moore SC, Huang WY, Haiman CA, Stern MC, Eliassen AH, Mucci LA, Aben KK, Galesloot TE, UROMOL Consortium, Verma A, Yoshino S, Hikino K, Terao C, Rafnar T, Matsuda K, Shuin T, Garcia-Closas M, Real FX, Kiemeney LA, Chanock SJ, Malats N, Silverman DT, Dyrskjot L, Rothman N, Damrauer SM, Koutros S, Damrauer JS. PMID: 42706231 [PubMed - indexed for MEDLINE]
	Re: Rana R. McKay, Karla V. Ballman, Pamela J. Atherton, et al. Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Renal Cell Carcinoma with Bone Metastases: RADICAL (Alliance A031801). J Clin Oncol. 2026;44:2341-52. Eur Urol Roviello G, Antonuzzo L. PMID: 42706004 [PubMed - as supplied by publisher]

Articles 1 - 20 / 181311

Page 1 of 9066



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy